Fluticasone propionate is a corticosteroid with the potential for topical treatment of ulcerative colitis because of low systemic bioavailability. The drug was compared with prednisolone in the management of active left sided or total ulcerative colitis. Two hundred and five patients were studied in the multicentre four week double blind study. Prednisolone was given in a dose of 40 mg daily orally, reducing over four weeks to 10 or 20 mg. Fluticasone propionate was given in an oral daily dose of 20 mg. The primary end point was the investigator's overall assessment of response. Patient's assessment, sigmoidoscopic appearance, and histology were also studied. Patients improved more rapidly with prednisolone. Differences between the two groups were significant at two weeks. At four weeks differences were not significant, but there was a trend in favour ofprednisolone. Corticosteroid side effects were minimal in the fluticasone propionate group, and there was minimal suppression of the hypothalamic pituitary adrenal axis. Fluticasone propionate 20 mg daily is not as effective in the treatment of active ulcerative colitis as prednisolone tapering from 40 mg daily to 10 or 20 mg. The complete absence of suppression of the corticoadrenal axis by fluticasone propionate was encouraging, however, and a higher dosage schedule should be assessed. (Gut 1993; 34: 125-128) Corticosteroid drugs are the most effective and widely used treatment for acute relapse ofulcerative colitis. High dosage or prolonged treatment is associated with a range of side effects. Topically active corticosteroids, with reduced systemic bioavailability, should have fewer side effects, and there is evidence that enema preparations of corticosteroid drugs with metabolism in gut wall or liver are effective in distal colitis. [1] [2] [3] 
assessed. (Gut 1993; 34: 125-128) Corticosteroid drugs are the most effective and widely used treatment for acute relapse ofulcerative colitis. High dosage or prolonged treatment is associated with a range of side effects. Topically active corticosteroids, with reduced systemic bioavailability, should have fewer side effects, and there is evidence that enema preparations of corticosteroid drugs with metabolism in gut wall or liver are effective in distal colitis. [1] [2] [3] Fluticasone propionate is a potent topically active fluorinated corticosteroid with low systemic bioavailability after oral administration, partly because of malabsorption, and partly because of extensive first pass metabolism. A significant proportion of the drug reaches the colon. This study was designed to compare the efficacy and safety of oral fluticasone propionate with prednisolone over a four week period in the treatment of active colitis.
Methods
The study was a multicentre randomised double blind parallel group trial of oral fluticasone propionate (5 mg four times daily) v prednisolone in reducing dosage. Ethical committee approval was obtained from 24 participating centres in the United Kingdom and Eire, and informed written consent was obtained from patients.
PATIENTS
The patients studied had active ulcerative colitis affecting at least the left side of the colon. Outpatients, with three or more bowel actions daily, passing liquid or semiformed stool were considered for trial entry. Patients who had taken corticosteroids in a daily dosage equivalent to 10 mg or more ofprednisolone orally, or 20 mg rectally in the previous 14 days were not included. The other major exclusion criteria were Crohn's disease, pregnancy, or concomitant serious medical conditions. Sigmoidoscopy scores showed significant differences in favour of prednisolone at weeks two and four (Table II) in the intention to treat analysis. In the analysis according to protocol, however, the difference in favour of prednisolone was significant at week two (p=002 1), but not at week four (p=0¢ 12). At week four the histological appearance of the biopsy specimens of 39% of patients receiving prednisolone had improved, compared with 19% in the fluticasone propionate group (p=0 -004). Differences in biopsy vascularity did not differ significantly between the two groups at week four.
SAFETY
More corticosteroid associated effects were seen in the prednisolone group: of the 100 patients, seven patients had facial swelling, four had facial flushing, one had confusion, and one increased hair growth. There were no such effects in the fluticasone group.
At entry, blood pressure was similar in both groups. At four weeks, systolic pressure (Table III) .
There were no deaths during the study, but two patients died shortly afterwards. A 72 year old woman died of a perforated colon 11 days after completing the trial, despite continuing prednisolone treatment. A 55 year old woman was withdrawn from the study at day 22, and treated with oral prednisolone. Ten days later she was admitted and given intravenous steroids, and died of presumed septicaemia shortly after a laparotomy (day 38). Both had been taking fluticasone propionate during the trial, but the investigators considered the deaths were caused by disease activity rather than the treatment received.
Discussion
There was improvement in both patient groups during the trial, with 63% and 77% of patients (fluticasone propionate and prednisolone respectively) improved or in remission, as assessed by the investigator at week four. Improvement occurred earlier in the prednisolone group, and at two weeks there was a significant difference in the investigator's assessments in favour of prednisolone. At four weeks the difference was no longer significant. It is possible that the closure of the efficacy gap at four weeks was because of the reduction in dosage in the prednisolone group, but also because fluticasone propionate acted more slowly. Overall, however, there was a trend for prednisolone to be more effective than fluticasone propionate. Sigmoidoscopic appearance and patients' symptoms were significantly better in the prednisolone group at two and four weeks. Biopsy inflammation score was significantly better, but vascularity score did not differ between the two treatments. Data from the 159 patients adhering fully to the protocol gave similar conclusions.
The majority of side effects were minor, but there was a marked absence of corticosteroid effects and hypothalamic pituitary adrenal axis suppression in the fluticasone propionate group. The two deaths after the trial were related to severe ulcerative colitis, and unlikely to have been drug related.
There Although it may not be possible to achieve therapeutic effects in the colon with this formulation, small bowel luminal concentration may be higher, and might account for the reports of possible benefit in small numbers of patients with coeliac and Crohn's disease.7" A larger trial in Crohn's disease is being evaluated. Although side effects in our study were minimal, oral fluticasone propionate 5 mg four times daily was not as effective as prednisolone in standard doses in the treatment of ulcerative colitis. Further studies to find a more effective topically active oral preparation are needed. 
